IBA showcases how to position a healthcare center at the forefront of cancer care at the ESTRO Conference 2018

Proton therapy

Louvain-la-Neuve, Belgium, and Barcelona, Spain, April 20, 2018 – IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, will demonstrate how to secure the performance, the investment and the future of establishing a proton therapy center at the 37th Annual European Society for Radiotherapy & Oncology (ESTRO) Meeting and Exhibition being held in Barcelona from 20-24 April, 2018.

Proton therapy is considered to be one of the most advanced forms of radiation therapy. When investing in a technology that will last for over 30 years, the selection of the right partner is a crucial step in the buying process. During the ESTRO meeting, proton therapy practitioners will share their experience about securing, installing and operating a proton therapy center with IBA during open sessions on the IBA booth as well as at the IBA Symposium. Aiming to offer seamlessly integrated proton therapy solutions, IBA will showcase the latest advances in its partnerships with the best leaders in radiation oncology at its booth, #1400.


Latest news from proton therapy practitioners
Securing the performance in proton therapy
After a fast installation of the Proteus®PLUS* solution by IBA, the University Medical Center Groningen (UMCG) Proton Therapy Center successfully treated the  first patient in The Netherlands in January 2018 and announces today the acceptance of the center’s second proton therapy room. Benefiting from a series of some of the world’s most advanced technology in proton therapy, the number of patients being treated at the center is ramping up quickly and will continue to rise with the additional treatment capacity.

Stefan Both, Professor & Head of Medical Physics at UMCG, will share his experience of UMCG’s path towards a SMART Proton Pencil Beam Scanning Clinic on the IBA booth, #1400 on Saturday, April 21st, from 10:00 AM to 10:30 AM.

Securing the investment in proton therapy
On April 11th, 2018, following a record nine month installation program by IBA, Proton Partners International announced it has treated the first patient in the UK with high energy proton beam therapy. The first patient was treated on the Proteus®ONE* solution at Rutherford Cancer Centre in Newport, South Wales. The patients benefit from the latest Intensity Modulated Proton Therapy (IMPT) to adjust the depth and intensity of the beam to the shape of the tumor. Proteus®ONE solution includes Pencil Beam Scanning (PBS) and Cone Beam CT (CBCT) capabilities making Proteus®ONE the only compact solution ready for adaptive treatment. Proton Partners International plans to build eight centers in the UK to provide a treatment center within 90 minutes of any patient’s home.

 John Pettingell, Chief Physicist & Head of Radiotherapy at the Rutherford Cancer Centres, will describe his experience in delivering the UKs first high energy proton therapy service on Saturday, April 21st, from 3:45 PM to 4:15 PM at IBA’s booth, #1400.

Securing the future in proton therapy

OncoRay – National Center for Radiation Research in Oncology, Dresden, Germany, is a leading research center with very advanced research in particle physics and radiation therapy. OncoRay is jointly operated by the Faculty of Medicine and the University Hospital Carl Gustav Carus at the Technical University Dresden and the Helmholtz-Zentrum Dresden-Rossendorf, Dresden. As part of the joint R&D program with IBA, OncoRay is currently working on the development of an MR-integrated proton therapy solution.

Aswin Hoffmann, Head of MR-Therapy Research at OncoRay will share the latest advances on this project related to a proof of concept with the first in-beam MRI on Sunday, April 22nd, from 3:45 PM to 4:15 PM at IBA’s booth, #1400.


Partnering with key market leaders in radiation oncology for optimal healthcare solutions
Following its open integration approach, IBA will showcase multiple workflow solutions to integrate proton therapy in the clinic.

IBA offers perfect integration with Elekta’s MOSAIQ® oncology information system that will be demonstrated at IBA’s booth. IBA and Elekta have signed a memorandum of understanding in order to develop, among others, new functionalities for proton therapy treatment in Elekta’s Monaco® treatment planning system and MOSAIQ® oncology information system and provide clinical pathway-driven adaptive particle therapy. The purpose is to offer a seamless experience across modalities for comprehensive radiotherapy departments and further improve patient care.

IBA is in a long-term strategic collaboration with Philips. By combining their respective expertise in image guidance and therapy, Philips and IBA continue to co-innovate in diagnostic and therapeutic oncology solutions with the ultimate objective of enabling more effective and personalized cancer care. Proton Partners International chose to partner with IBA and Philips in an ambitious plan to build a network of state-of-the-art proton therapy centers in the UK, and in the Middle East. All centers will integrate IBA’s latest Image Guided IMPT combined with Philips’ Pinnacle3 Treatment Planning System, as well as Philips’ Big Bore CT, and Philips’ Ambient Experience, a patient-focused healthcare environment designed to create a more comfortable and soothing experience for patients and staff.

IBA is partnering with RaySearch Laboratories AB (publ) to advance adaptive proton therapy in combining respective technologies. In both RayStation® and RayCare**, as well as in the IBA delivery solutions, combined features dedicated software interfaces allow for seamless workflow integration with optimized performance. A real-time demonstration will be displayed at IBA’s booth.

For more information about the online adaptive proton therapy workflow, read the press release.


IBA Proton Therapy Conference
On Saturday, April 21st, 2018, IBA is hosting a symposium in Barcelona with presentations from experienced speakers in proton therapy:

  • Professor Debus, from Heidelberg University Hospital, will explain the benefits of proton therapy for key clinical indications;
  • The model based approach for patient selection will be presented by Professor Langendijk from the University Medical Center in Groningen;
  • Professor Depuydt, from ParTICLe Proton Therapy UZ Leuven, will describe the integration of proton therapy in an existing oncology center.

Registration to the IBA proton therapy event is available here.


About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com


*Proteus®ONE and Proteus®PLUS are brand names of Proteus 235

**Subject to regulatory clearance in some markets


For further information, please contact:

Aymeric Harmant
Global Marketing Director
+32 10 203 796